Absci Corporation (NASDAQ:ABSI) is among the 12 Best Genomics Stocks to Invest In. Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial Absci Corporation (NASDAQ:ABSI) announced on December 4, 2025, that the first healthy volunteers had been dosed in the Phase 1/2a HEADLINE clinical trial investigating ABS-201, an experimental anti-prolactin receptor antibody built on its generative AI system. The Phase 1/2a trial is intended to evaluate effectiveness, pharmacokinetics ...